作者：
Ilyas,M. [1]
;
Grabsch,H. [2]
;
Ellis,I.O. [3]
;
Womack,C. [4]
;
Brown,R. [5]
;
Berney,D. [6]
;
Fennell,D. [7]
;
Salto-Tellez,M. [8]
;
Jenkins,M. [9]
;
Landberg,G. [10]
;
Byers,R. [11]
;
Treanor,D. [12]
;
Harrison,D. [13]
;
Green,A.R. ;
Ball,G. ;
Hamilton,P.
作者单位：
PathXL Ltd, Northern Ireland Science Park, Belfast, United Kingdom, Bioimaging and Informatics
[1]
Epigenetics Unit, 4th Floor IRDB, Hammersmith Hospital, London, United Kingdom
[2]
John Van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent
[3]
Department of Histopathology, Manchester Royal Infirmary, Manchester, United Kingdom
[4]
Department of Pathology, Barts and The London School of Medicine and Dentistry, London, United
[5]
Section of Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, St James's
[6]
St James University Hospital, Leeds Institute of Molecular Medicine, Leeds, United Kingdom
[7]
School of Medicine, University of St Andrews, St Andrews, Fife, United Kingdom
[8]
University of Leicester and Leicester University Hospitals, Leicester, United Kingdom
[9]
AstraZeneca Oncology Innovative Medicines, Macclesfield, Cheshire, United Kingdom
[10]
Centre for Cancer Research and Cell Biology, University Road, Belfast, United Kingdom
[11]
School of Molecular Medical Sciences, Queen's Medical Centre, Nottingham University, Nottingham
[12]
Department of Histopathology, Manchester Royal Infirmary, Manchester, United Kingdom, AstraZeneca
[13]
发布时间
2013-11-20
换一批
